-
公开(公告)号：US06423315B1
公开(公告)日：2002-07-23
申请号：US08425175
申请日：1995-04-20
申请人： Linda K. Myers , Jerome M. Seyer , Andrew H. Kang
发明人： Linda K. Myers , Jerome M. Seyer , Andrew H. Kang
IPC分类号： A61K3808
CPC分类号： C07K14/78 , A61K38/00 , Y10S424/81 , Y10S514/825 , Y10S530/806
摘要： Peptides that are capable of suppressing autoimmune arthritis are disclosed. The polypeptides described by the present invention which are capable of suppressing autoimmune arthritis in mammals include analogues of CII 245-270. The peptides do not provoke a material immunogenic response from T cells, and thus are useful therapeutic agents for suppressing autoimmune arthritis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, spondylo arthritis, relapsing polychondritis and other connective tissue diseases. A method of surpressing autoimmune arthritis in mammals is also provided by the present invention.
摘要翻译： 公开了能够抑制自身免疫性关节炎的肽。 本发明描述的能够抑制哺乳动物自身免疫性关节炎的多肽包括CII 245-270的类似物。 肽不会引起T细胞的物质免疫原性反应，因此是抑制自身免疫性关节炎，类风湿性关节炎，幼年型关节炎，牛皮癣关节炎，脊椎关节炎，复发性软骨炎等结缔组织疾病的有用治疗剂。 哺乳动物抑制自身免疫性关节炎的方法也由本发明提供。
-
公开(公告)号：US5160483A
公开(公告)日：1992-11-03
申请号：US697642
申请日：1991-05-07
IPC分类号： A61K38/00 , C07K14/525
CPC分类号： C07K14/525 , A61K38/00
摘要： A method and composition for promoting the healing of an open wound, such as a fresh surgical incision, a decubitus ulcer, or a diabetes ulcer. The method includes applying to the wound a therapeutically effective amount of a composition comprising a protein fragment of tumor necrosis factor .alpha.(TNF-.alpha.) including amino acids 31 through 68 SEQ ID NO.: 1. The composition may be applied topically or injected locally into a wound or ulcer site. A preferred composition includes a carrier medium selected from sterile water, sterile saline, and albumin. Topical formulations are administered as sprays, gels, ointments or salves.
摘要翻译： 用于促进开放性伤口愈合的方法和组合物，例如新鲜的手术切口，褥疮溃疡或糖尿病溃疡。 该方法包括向伤口施用治疗有效量的包含肿瘤坏死因子α（TNF-α）的蛋白质片段的组合物，其包括SEQ ID NO：1的氨基酸31至68。组合物可局部施用或局部注射 进入伤口或溃疡部位。 优选的组合物包括选自无菌水，无菌盐水和白蛋白的载体介质。 局部制剂作为喷雾剂，凝胶剂，软膏或药膏施用。
-
3.发明授权
公开(公告)号：US5962025A
公开(公告)日：1999-10-05
申请号：US682021
申请日：1996-07-16
CPC分类号： A61K38/39 , Y10S514/801
摘要： The present invention is directed to a method and pharmaceutical formulations for the treatment of systemic sclerosis in mammals, by oral administration of collagen, including type I collagen, or biologically active peptide fragments thereof.
摘要翻译： 本发明涉及一种用于治疗哺乳动物系统性硬化症的方法和药物制剂，其通过口服胶原蛋白，包括I型胶原蛋白或其生物活性肽片段。
-
公开(公告)号：US20110195905A1
公开(公告)日：2011-08-11
申请号：US12914823
申请日：2010-10-28
IPC分类号： A61K38/17 , C07K14/435 , A61P19/02
CPC分类号： A61K38/16 , A61K38/1709
摘要： One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient.
摘要翻译： 治疗组合物的一个实施方案包含一种或多种APL，例如APL A12，用于治疗与关节炎相关的疾病或病症，包括类风湿性关节炎。 另一个实施方案包括在哺乳动物中诱导Th2型细胞因子分泌谱的方法，包括给予治疗量的A12类似物肽。 另一个实施方案包括产生功能性T调节细胞的方法，所述方法包括向RA患者施用治疗量的APL A12。
-
5.发明申请公开(公告)号：US20100179096A1
公开(公告)日：2010-07-15
申请号：US12749141
申请日：2010-03-29
CPC分类号： A61K38/39
摘要： The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis.
摘要翻译： 本发明首次证明口服I型胶原（CI）诱导患有系统性硬化症（SSc）的患者对CI的耐受性并改善了该疾病的临床表现。 因此，本发明提供了通过口服给予经历纤维化的组织的组织蛋白例如胶原来治疗纤维化疾病的方法。
-
6.发明授权公开(公告)号：US07718765B2
公开(公告)日：2010-05-18
申请号：US11600525
申请日：2006-11-16
CPC分类号： A61K38/39
摘要： The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis.
摘要翻译： 本发明首次证明口服I型胶原（CI）诱导患有系统性硬化症（SSc）的患者对CI的耐受性并改善了该疾病的临床表现。 因此，本发明提供了通过口服给予经历纤维化的组织的组织蛋白例如胶原来治疗纤维化疾病的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.027 秒)
